Ocrelizumab (Ocrevus®) is accepted for use within NHS Scotland

Source:
Scottish Medicines Consortium - SMC
Publisher:
Scottish Medicines Consortium
Publication date:
13 January 2020

Abstract

Ocrelizumab is accepted for use within NHS Scotland for the treatment of adult patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.